CardioExchange Archive

September 1st, 2013

Pretreatment with Prasugrel Not Indicated in NSTEMI

Larry Husten, PHD

Pretreatment prasugrel for NSTEMI was not effective in the ACCOAST trial.

---

July 16th, 2012

Ticagrelor Joins Clopidogrel and Prasugrel in Updated NSTEMI Guidelines

Larry Husten, PHD

Ticagrelor (Brilinta, AstraZeneca) gains equal standing with prasugrel (Effient, Lilly) and clopdiogrel in the newly released focused update of the ACCF/AHA guidelines for unstable angina and non-ST-elevation myocardial infarction (NSTEMI). The change had been widely anticipated since last year’s FDA approval of ticagrelor. “We have put it on equal footing with two other antiplatelet medications, clopidogrel […]

---

November 13th, 2011

ISAR-REACT 4: Bivalirudin Works Great, Less Bleeding

Richard A. Lange, MD, MBA

In the previously published REPLACE-2 and ACUITY trials, a trend was noted towards an increased incidence of ischemic complications with bivalirudin compared with glycoprotein IIb/IIIa treatment in high-risk patients undergoing PCI. The Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4 (ISAR-REACT 4) trial was designed to show whether abciximab plus unfractionated […]

---

April 10th, 2011

Questioning the Guidelines

scottwright109 and Hansie Mathelier, MD

CardioExchange welcomes R Scott Wright, the chair of the recently published focused update of the ACC/AHA Unstable Angina/NSTEMI guidelines. Dr. Wright generously agreed to answer questions about the guidelines posed by the CardioExchange editors. CardioExchange Editors: For clinicians reading this guidelines update, what would you highlight as the most important new or revised recommendations that should […]

---

March 28th, 2011

Updated Unstable Angina/Non-STEMI Guidelines Released by ACC & AHA

Larry Husten, PHD

The AHA and ACC have released a focused update of the 2007 guidelines for the management of unstable angina and non-STEMI. The guidelines incorporate new information from recent clinical trials, and deal with controversial topics such as the choice of antiplatelet agents, the use of platelet-function and genetic tests with antiplatelet agents, and the timing […]

---

November 8th, 2010

Non-STEMI Patients Delay Seeking Help Just As Long as STEMI Patients

Larry Husten, PHD

Non-STEMI patients delayed going to the hospital for as long in 2006 as they did in 2001, according to a report published in the Archives of Internal Medicine. Henry Ting and colleagues analyzed data from 104,622 non-STEMI patients enrolled in the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of […]

---

August 4th, 2010

Three Questions about Ticagrelor: Part 2 — Mori Krantz

Sanjay Kaul, MD

PLATO is one of the most impressive trials in recent years, demonstrating substantial benefits for ticagrelor over clopidogrel in a wide population of ACS patients. However, patients enrolled in the US were found to have no benefit from ticagrelor, and experts have been unable to agree on a cause. Possible factors could include much higher doses […]

---

August 3rd, 2010

Three Questions about Ticagrelor: Part 1 — Sanjay Kaul

Sanjay Kaul, MD

PLATO is one of the most impressive trials in recent years, demonstrating substantial benefits for ticagrelor over clopidogrel in a wide population of ACS patients. However, patients enrolled in the US showed no benefit from ticagrelor, and experts have been unable to agree on a cause. Possible factors could include much higher doses of aspirin used […]

---